Inhibrx Biosciences (INBX) Enterprise Value (2024 - 2026)

Inhibrx Biosciences (INBX) has reported Enterprise Value for 3 consecutive years, with -$124.2 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Enterprise Value rose 18.61% year-over-year to -$124.2 million; the TTM figure through Dec 2025 stood at -$124.2 million (up 18.61% YoY), while the FY2025 annual figure was -$124.2 million, up 18.61% from the prior year.
• Enterprise Value improved to -$124.2 million in Q4 2025 per INBX's latest filing, from -$153.1 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$124.2 million in Q4 2025 and bottomed at -$277.9 million in Q4 2023.
• Historically, Enterprise Value has averaged -$191.8 million across 3 years, with a median of -$191.4 million in 2024.
• Annual changes were most pronounced in 2024 — Enterprise Value soared 45.09% — and 2025, when it increased 17.76%.
• Inhibrx Biosciences' Enterprise Value stood at -$277.9 million in 2023, then jumped by 45.09% to -$152.6 million in 2024, then advanced by 18.61% to -$124.2 million in 2025.
• Business Quant data shows INBX's Enterprise Value at -$124.2 million in Q4 2025, -$153.1 million in Q3 2025, and -$186.6 million in Q2 2025.